. However, in multivariable analyses, treatment with a rhythm control strategy was not associated with discharge rhythm (HR 1.068, p = 0.77), p = 0.18) or mortality from day 30 to 1 year (HR 1.00, p = 0.99 (Cardiol J 2013; 20, 4: 439-446) 
Introduction
Atrial fi brillation (AF) is twice as prevalent among patients with chronic kidney disease (CKD) and over 10 times more prevalent in patients on dialysis than in the general population [1, 2] . In the Chronic Renal Insuffi ciency Cohort of 3,267 adult participants, nearly 1 in 5 participants had evidence of AF; age, female gender, and a history of cardiovascular disease were the major predictors of AF in the study. Also, among 956 outpatients with coronary artery disease in the Heart and Soul Study, kidney dysfunction was independently associated with prevalent AF [3] . Although each of these groups of patients is at high risk for cardiovascular mortality and morbidity, little is known about the impact of AF treatment strategy on clinical outcomes in patients with kidney disease. As such, the optimal management of AF in this population is unknown.
AF in the setting of acute myocardial infarction (MI) is associated with worse outcomes [4] . Although antiarrhythmic medications with or without electrical cardioversion may restore sinus rhythm (SR) in these patients, their ability to improve post-MI survival is unclear. In the Valsartan in Acute Myocardial Infarction (VALIANT) Trial, antiarrhythmic use was associated with excess short-term mortality in the peri-MI period but not long-term mortality [5] . Results from the Global Use of Strategies to Open Occluded Coronary Arteries III (GUSTO-III) AF substudy suggested a trend toward lower mortality with the use of sotalol and procainamide in post-MI patients with AF [6] . The effect of CKD on these outcomes is unknown. This is an issue of particular clinical signifi cance, because CKD itself is a risk factor for increased mortality after acute MI [7, 8] .
Using prospective data from the GUSTO-III trial, we conducted an analysis to investigate the use of a rhythm control strategy in patients with CKD and post-MI AF and to study its impact on the maintenance of SR, 30-day and 1-year mortality.
Methods

Study population
The GUSTO-III trial was an international study of over 15,000 patients treated for acute MI with ST-segment elevation or new left bundle-branch block and randomized to alteplase or reteplase therapy between October 13, 1995 and January 13, 1997 [9] . A cohort of 1,138 subjects who developed AF during the study period was enrolled into a prospective substudy of post-MI AF management [6] .
Patients were treated either with a rate control only strategy using atrioventricular nodal blocking agents or a rhythm control strategy using antiarrhythmic medications and/or electrical cardioversion. Treatment decisions were made by the primary medical team and were not randomized, but this pre-specifi ed observational analysis investigated outcomes including the maintenance of SR, and mortality at 30 days and 1 year post-MI. Patients were excluded from this analysis if they had longstanding persistent or permanent AF at study entry.
The details of patient enrollment and data collection have been previously described [9] . The Duke University Medical Center Institutional Review Board approved the study protocol, and all patients provided informed written consent for the collection of clinical data and blood samples before participation in the GUSTO-III trial.
Data collection
This was a prospective cohort analysis of outcomes in the GUSTO-III AF substudy, stratified by the presence or absence of CKD (defined as a calculated creatinine clearance below 60 mL/min/1.73 m 2 ) at the time of enrollment. The primary outcome measure was 1-year survival post AF onset. Secondary outcomes included 30-day survival post AF onset and the presence of SR at the time of hospital discharge or last stable rhythm prior to death. The goal of the proposed analysis was to investigate the use of a rate vs. rhythm control strategy in patients with post-MI AF and to study the impact of CKD and treatment strategy on the maintenance of SR, 30-day and 1-year mortality. Data collected as part of the substudy included the use of ventricular rate controlling agents (beta-blockers, calcium antagonists, or digitalis), the use of any antiarrhythmic agent (procainamide, quinidine, disopyramide, encainide, fl ecainide, propafenone, sotalol and amiodarone) or electrical cardioversion for rhythm control, the use of antiplatelet and anticoagulant medications at hospital discharge, and the cardiac rhythm at hospital discharge or the last stable rhythm recorded before deterioration to in-hospital death.
Statistical analysis
Baseline variables were compared between groups using the Wilcoxon rank-sum test for continuous variables and the Pearson c 2 or Exact test for categorical variables. The product-limit method was used to model the event-free survival of subjects, and survival curves were compared using the log-rank test. Factors associated with survival time after the onset of AF were assessed in univariate and multivariable Cox proportional hazards Eric S. Williams et al., Rate vs. rhythm control in atrial fi brillation and chronic kidney disease models. In addition to CKD and treatment strategy, covariates previously known to be associated with mortality in the GUSTO trial were included in the models [9, 10] . Additionally, factors associated with maintenance of SR at hospital discharge were modeled using multivariable logistic regression. Candidate variables selected by the study investigators were considered in multivariable stepwise regression models, and a 2-tailed p value of < 0.05 was considered statistically signifi cant. Analyses were performed using SAS, version 9.2, software (SAS Institute, Cary, NC).
Results
Population characteristics
Of the 1,138 patients enrolled in the GUSTO-III AF substudy, 153 were excluded due to a history of longstanding persistent or permanent AF. Thus, 985 patients met our inclusion criteria and were represented in this analysis. Of these patients, 639 (65%) were treated with a rate control only strategy, and 346 (35%) were treated with a rhythm control strategy during the index hospitalization. The baseline characteristics of the cohort are shown in Table 1 . Subjects who received rhythm control on average had higher heart rates at enrollment and were more likely to present with an anterior MI than those who received a rate control strategy; otherwise, no signifi cant differences in demographic characteristics or baseline medical conditions were noted between the two groups. Additionally, there was no signifi cant difference in the percentage of patients managed with a rhythm control strategy in the CKD vs. non-CKD groups (34% vs. 36%). Subjects with CKD had a mean creatinine clearance of 45 mL/min, were older, more likely to be white and female, tended to have slightly worse Killip class, and were less likely to have a history of hyperlipidemia and smoking than subjects without CKD. Table 2 summarizes the details of the treatment strategy in the rhythm control group. In this group, 30% (103) received electrical cardioversion, 55% of whom had a primary cardioversion strategy, as opposed to antiarrhythmic medication use followed by cardioversion. Amiodarone and procainamide were the principal antiarrhythmic agents used in the rhythm control cohort, used in 70% of subjects. Procainamide was used less frequently in CKD patients than in non-CKD patients (p = 0.025); no difference was seen with the use of other antiarrhythmic agents. Class IC antiarrhythmics were used infrequently in the cohort. Specifi cally, fl ecainide was only used in 2 subjects, and encainide was not used at all, very likely due to their known association with increased mortality in the post-MI setting. Table 3 shows the use of antiplatelet and anticoagulant medications at hospital discharge, in each subgroup. Notably, patients in the rhythm control group were more likely to receive warfarin at discharge than those in the rate control group; the rates of use of other antithrombotics in the two groups were similar. In addition, patients with CKD were less likely to receive aspirin and other antiplatelet medication than those without CKD; warfarin and subcutaneous heparin, however, were used similarly in CKD and non-CKD patients.
Management strategy
Survival analysis
At follow-up, there were a total of 154 (15.6%) deaths within 30 days and 222 (22.5%) deaths at 1 year. Kaplan-Meier curves for survival from the time of AF onset up to 1 year are displayed in the Figure 1 . Observed survival differences were largest between those with and without CKD (log-rank p-value < 0.001), with non-signifi cant differences between rate and rhythm control strategies (log-rank p-value = 0.109). Table 4 shows that in univariate analysis, there was a statistically signifi cant association between CKD and increased mortality at 30 days (unadjusted HR 2.4, 95% CI 1.7-3.3, p < 0.001) and from day 30 to 1 year (unadjusted HR 1.7, 95% CI 1.1-2.8, p = 0.027). However, in multivariable analyses, the association between CKD and mortality became non-signifi cant. In addition, regardless of kidney disease status, treatment with a rate vs. rhythm control strategy was not signifi cantly associated with mortality (p value for interaction between CKD and treatment strategy = 0.89 for 30-day and 0.38 for 1-year mortality).
Effi cacy of rhythm control
Sinus rhythm was present at hospital discharge in 487 (76%) of patients treated with a rate control strategy, vs. 276 (80%) in those treated with rhythm control (p = 0.20). In univariate analysis, CKD was associated with a lower odds of SR at discharge (unadjusted OR 0.56, 95% CI 0.38-0.84, p < 0.001), as shown in Table 5 . In multivariable analysis that adjusted for potential confounders, however, treatment with a rhythm control strategy was not associated with discharge rhythm (HR 1.068, 95% CI 0.69-1.66, p = 0.77), 30-day mortality (HR 0.78, 95% CI 0.54-1.12, p = 0.18) or mortality from day 30 to 1 year (HR 1.00, 95% CI Tables 4, 5 ). Additionally, the lack of association between treatment strategy and discharge rhythm was not signifi cantly different in CKD patients (p value for interaction between CKD and treatment strategy = 0.30).
Sensitivity analysis
Regression analyses were repeated to examine the effect of moderate to severe CKD, defi ned as a creatinine clearance < 45 mL/min, on clinical outcomes (Tables 6, 7) . In multivariable analysis, there was an almost 2-fold increase in mortality associated with moderate to severe CKD at 30 days (HR 1.93, 95% CI 1.28-2.92, p = 0.002) and from day 30 to 1 year (HR 1.93, 95% CI 1.02-3.66, p = 0.04). There was no signifi cant association between treatment with a rate vs. rhythm control strategy and mortality in the subgroup with creatinine clearance < 45 mL/min (p value for interaction between moderate to severe CKD and treatment strategy = 0.40 both for 30-day and for 1-year mortality). There was a difference, however, in the effect of treatment strategy on discharge rhythm in this subgroup. While in the overall cohort there was no association between treatment strategy and discharge rhythm, in the patients with moderate to severe CKD, there was a lower probability of SR at discharge with a rhythm control strategy (adjusted OR 0.43, 95% CI 0.19-0.99, p value for interaction between moderate to severe CKD and treatment strategy = 0.01).
Discussion
In this prospective cohort analysis of patients with AF complicating acute MI, we examined the impact of both CKD and treatment with a primary rate or rhythm control strategy on clinical outcomes. Over a third of subjects in the GUSTO-III substudy who developed AF were treated with a rhythm control strategy, which primarily consisted of antiarrhythmic agents such as amiodarone or procainamide. Thirty percent of patients received electrical cardioversion, either alone or with adjunctive antiarrhythmic therapy. There was no signifi cant difference in the use of rhythm control between the CKD and non-CKD arms. In our study, treatment with a rate or rhythm control strategy was not signifi cantly associated with 30-day and 1-year outcomes in multivariable analyses. In unadjusted analyses, subjects with CKD had increased mortality and were less likely to maintain SR at discharge; in multivariable analysis there was no signifi cant association between CKD and either outcome, regardless of treatment strategy. A sensitivity analysis was performed to investigate the outcomes of subjects with moderate to severe CKD, defi ned as creatinine clearance < 45 mL/min, which found a lower likelihood of maintaining SR at discharge with a rhythm control strategy in multivariable analysis. While AF diagnosed in the setting of acute MI has been associated with adverse outcomes [4, [10] [11] [12] [13] , the optimal treatment strategy of AF in this setting is unclear, with some studies suggesting an increased harm with antiarrhythmic therapy [5] , and others either neutral or suggesting a possible benefi t [6, 14] . It is known that the development of post-MI AF is associated with other factors that independently portend a more complicated clinical course, such as older age, left ventricular dysfunction, and worsening heart failure [4, 15] . To the extent that AF is a marker of these adverse prognostic factors, treatment directed at controlling AF per se, may not necessarily improve clinical outcomes. In addition, the risk of pro-arrhythmia related to antiarrhythmic medication use has to be weighed against any potential benefi t of restoring and maintaining SR. In the present study, there was no signifi cant association between AF treatment strategy and either short-or long-term mortality. This suggests that, while an aggressive strategy of rhythm control may not be indicated in the routine management of all patients with post-MI AF, it is certainly reasonable to consider in the short-term management of select patients in the post-MI setting, especially in patients who are symptomatic despite adequate rate control [6] .
CKD is both a risk factor for AF [2, 16, 17] and an independent predictor of adverse outcomes after acute MI [8, [18] [19] [20] . The risks of antiarrhythmic therapy may be magnifi ed in patients with CKD, owing to the need for renal dose adjustment of certain antiarrhythmic agents [21] , as well as to the co-morbidity that often accompanies CKD and that may promote pro-arrhythmia. The development of fi brosis and left ventricular hypertrophy associated with kidney disease is hypothesized to predispose CKD patients to cardiac arrhythmia and sudden death by its effects on the QT interval and QT dispersion [22, 23] . As a result, evidence from clinical trials on rate and rhythm control strategies in AF may not be generalizable to patients with impaired renal function, so data are limited in this regard. This is the fi rst study we are aware of that addresses the safety and effi cacy of rate vs. rhythm control of AF in CKD patients. Notably, despite high post-MI mortality rates in this cohort (15.6% at 30 days and 22.5% at 1 year), there was no suggestion that CKD patients were at higher risk of short-or long-term mortality when treated with either a primary rate or rhythm control strategy. Interestingly, regardless of CKD status, there was no signifi cant overall impact of a rhythm control strategy on discharge rhythm in this population. This fi nding does not rule out a possible benefi t of rhythm control in reducing the overall duration and burden of AF during the hospitalization or improving quality of life and/or functional status, although this was not specifi cally addressed in our analysis. Results of the subgroup with moderate to severe CKD suggested that a rhythm control strategy was associated with a lower probability of maintaining SR at discharge. While results of any subgroup should be interpreted with caution, this is an intriguing fi nding that should be the subject of future prospective studies on antiarrhythmic management in CKD patients.
Limitations of the study
As with any observational study, the present one is not without some limitations. First, although this was a pre-specifi ed prospective analysis of AF management and outcomes, treatment with rate vs. rhythm control was not randomized and the potential for confounding exists. This is mitigated somewhat by the multivariable regression modeling to adjust for known confounders in the cohort. Second, while in-hospital management was recorded and accounted for in the analysis, the impact of interventions after hospital discharge on 1-year mortality, such as additional medications, or cross-over from rate control to a rhythm control strategy, was not known. Also, creatinine clearance Cardiology Journal 2013, Vol. 20, No. 4 was calculated using serum creatinine measurements at the time of study enrollment but this may not accurately refl ect steady-state renal function. Finally, amiodarone and procainamide were the principal antiarrhythmic medications used in GUSTO-III and thus results in this cohort may not be generalizable to contemporary practice, where agents such as dofetilide, sotalol, and dronedarone are now commonly used in the post-MI setting.
Conclusions
In patients with post-MI AF, treatment with a rhythm or rate control strategy does not significantly impact short-term or long-term mortality, regardless of kidney disease status. Future randomized trials to investigate the optimal management of post-MI AF in patients with CKD are needed.
